Stay updated with breaking news from Thomas Biegi. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
EQS-News: MorphoSys AG / Key word(s): MiscellaneousGSK, MorphoSys’ Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis 27.10.2022 / 08:50 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich,...
PLANEGG / MUNICH, GERMANY / ACCESSWIRE / October 27, 2022 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announced today that its licensing partner, GSK plc (GSK), provided an update on the ContRAst phase III program
EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors 27.10.2022 / 22:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media Re...
The findings, including encouraging preliminary efficacy data in various tumor types, were presented during the 34th EORTC-NCI-AACR SymposiumPLANEGG/MUNICH, GERMANY / ACCESSWIRE / October 27, 2022 / MorphoSys
MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022Preliminary Q3 2022 Monjuvi U.S. net product sales of US$ 22.2 million (€ 21.9 million)Anticipated full year